Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Auderghem – page 60

1 992 clinical trials in Auderghem, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Auderghem at a glance
1 992
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 992 trials in Auderghem

Open in trial search

Migraine+2

Recruiting

Study on Long-term Safety and Tolerability of Atogepant for Children and Teens (Ages 6-17) with Migraine

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Atogepant
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Medulloblastoma

Recruiting

Study on the Effectiveness of Bevacizumab and Drug Combination for Children with Recurrent or Progressive Medulloblastoma, Ependymoma, and ATRT

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Bevacizumab
  • Sponsor:Medical University Of Vienna

Study on ONC201 and Everolimus with Radiotherapy for Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Other Diffuse Midline Gliomas in Children, Adolescents, and Adults

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dordaviprone
  • Sponsor:Institut Gustave Roussy

Study on Random Start Ovarian Stimulation with Follitropin Alfa, Dydrogesterone, and Triptorelin Acetate for Women Undergoing Elective Oocyte Cryopreservation to Prevent Infertility

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Dydrogesterone
  • Sponsor:UZ Brussel

Study of prucalopride in patients with gastro-esophageal reflux disease who have incomplete response to standard acid-reducing therapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Prucalopride
  • Sponsor:UZ Leuven

Endometrial cancer+38

Recruiting

Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:DS-3939A
  • Sponsor:Daiichi Sankyo Inc.

Study on Tioguanine and Drug Combination for Patients Aged 0-45 with Newly Diagnosed Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Karolinska University Hospital

Study on Posaconazole and Fluconazole for Preventing Fungal Infections in Patients with Acute Myeloid Leukemia

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Fluconazole
  • Sponsor:Centre Hospitalier Universitaire Vaudois

Study of petosemtamab alone or with drug combination for patients with advanced colorectal cancer and other solid tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Genmab A/S

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Triple Negative Breast Cancer with Residual Disease After Surgery and Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Gilead Sciences Inc.

Study on Citalopram for Patients with Reflux Hypersensitivity or Functional Heartburn Not Fully Helped by Proton Pump Inhibitors

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Citalopram
  • Sponsor:UZ Leuven

Neoplasm

Recruiting

Study on Long-Term Safety of BI 907828 for Patients with Solid Tumors Who Previously Participated in a Study with This Medicine

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Brigimadlin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Auderghem

What the registry says about research in the country

01 Neoplasms

In Auderghem, researchers are concentrating on lung cancer, specifically Non‑Small Cell Lung Cancer and small cell lung cancer. The two active studies compare new immune‑targeted agents such as pumitamig and obrixtamig against established therapies like pembrolizumab and standard chemotherapy, aiming to improve overall survival and disease control.

  • Comparative efficacy of novel immunotherapies
  • Evaluation of survival benefit in advanced disease
  • Biomarker‑guided patient selection (e.g., DLL3 expression)
  • Combination regimens with checkpoint inhibitors

Both trials are actively recruiting, reflecting a growing commitment in Auderghem to advance treatment options for patients with aggressive lung cancers.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.